<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Daratumumab and hyaluronidase (subcutaneous): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Daratumumab and hyaluronidase (subcutaneous): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Daratumumab and hyaluronidase (subcutaneous): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="128155" href="/d/html/128155.html" rel="external">see "Daratumumab and hyaluronidase (subcutaneous): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54369806"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Darzalex Faspro</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F54987164"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Darzalex SC</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F54367994"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-CD38;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F54456357"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Premedicate 1 to 3 hours prior to each infusion with a corticosteroid, an oral antipyretic, and an oral or IV antihistamine; postdosing, administer an oral corticosteroid (based on regimen and/or medical history) to reduce the risk of delayed infusion reactions (see “Premedication” and “Post-dose Medication” below). To prevent herpes zoster reactivation, initiate antiviral prophylaxis within 1 week after starting daratumumab/hyaluronidase and continue for 3 months following completion of treatment. Refer to Dexamethasone, Lenalidomide, Thalidomide, Pomalidomide, Bortezomib, Carfilzomib, Cyclophosphamide, Melphalan, and/or Prednisone monographs for dosing when used as a part of daratumumab-based combination therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Do <b>NOT</b> substitute daratumumab/hyaluronidase (for subcutaneous use) with daratumumab (IV); products have different dosing and are <b>NOT</b> interchangeable.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="66eb9cb6-806e-4e59-8db9-961e62c5e7e0">Light chain amyloidosis, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Light chain amyloidosis, newly diagnosed: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with bortezomib, cyclophosphamide and dexamethasone (Dh-VCd): </i></p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 1 to 8: <b>SUBQ: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once weekly for a total of 8 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 9 to 24: <b>SUBQ</b>
<b>:</b> Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 2 weeks (beginning week 9) for a total of 8 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 25 and beyond: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 4 weeks (beginning week 25) until disease progression or unacceptable toxicity or a maximum of 2 years.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="803bf39b-990a-4158-995f-5bf6163854af">Multiple myeloma, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, newly diagnosed:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with bortezomib, thalidomide, and dexamethasone (Dh-VTd); in patients eligible for autologous stem cell transplant:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Induction:</p>
<p style="text-indent:-2em;margin-left:8em;">Weeks 1 to 8: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once weekly for a total of 8 doses.</p>
<p style="text-indent:-2em;margin-left:8em;">Weeks 9 to 16: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 2 weeks (beginning week 9) for a total of 4 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Consolidation (following autologous stem cell transplant): Weeks 1 to 8: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 2 weeks for a total of 4 doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with lenalidomide and dexamethasone (Dh-Rd); in patients ineligible for autologous stem cell transplant: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 1 to 8: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once weekly for a total of 8 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 9 to 24: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 2 weeks (beginning week 9) for a total of 8 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 25 and beyond: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 4 weeks (beginning week 25) until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with bortezomib, melphalan, and prednisone (Dh-VMP); in patients ineligible for autologous stem cell transplant</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33216361']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33216361'])">Ref</a></span>)<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 1 to 6: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once weekly for a total of 6 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 7 to 54: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 3 weeks (beginning week 7) for a total of 16 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 55 and beyond: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 4 weeks (beginning week 55) until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1c12cde-98c7-41e9-80b8-0893e9934cc7">Multiple myeloma, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, relapsed/refractory:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>As monotherapy; in patients who have received at least 3 prior lines of therapy</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32213342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32213342'])">Ref</a></span>)<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 1 to 8: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once weekly for a total of 8 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 9 to 24: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 2 weeks (beginning week 9) for a total of 8 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 25 and beyond: <b>SUBQ</b>
<b>:</b> Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 4 weeks (beginning week 25) until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with lenalidomide and dexamethasone (Dh-Rd); in patients who have received at least 1 prior therapy</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33216361']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33216361'])">Ref</a></span>)<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 1 to 8: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once weekly for a total of 8 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 9 to 24: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 2 weeks (beginning week 9) for a total of 8 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 25 and beyond: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 4 weeks (beginning week 25) until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with carfilzomib and dexamethasone (Dh-Kd); in patients who have received 1 to 3 prior lines of therapy</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moreau.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moreau.1'])">Ref</a></span>)<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 1 to 8: <b>SUBQ: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once weekly for a total of 8 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 9 to 24: <b>SUBQ: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 2 weeks (beginning week 9) for a total of 8 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 25 and beyond: <b>SUBQ: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 4 weeks (beginning week 25) until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with pomalidomide and dexamethasone (Dh-Pd); in patients who have received at least 1 prior therapy, including lenalidomide and a proteosome inhibitor</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34087126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34087126'])">Ref</a></span>)<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 1 to 8: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once weekly for a total of 8 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 9 to 24: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 2 weeks (beginning week 9) for a total of 8 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 25 and beyond: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 4 weeks (beginning week 25) until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with bortezomib and dexamethasone (Dh-Vd); in patients who have received at least 1 prior therapy: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 1 to 9: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once weekly for a total of 9 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 10 to 24: <b>SUBQ</b>
<b>: </b>Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 3 weeks (beginning week 10) for a total of 5 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weeks 25 and beyond: <b>SUBQ</b>
<b>:</b> Daratumumab 1,800 mg/hyaluronidase 30,000 units once every 4 weeks (beginning week 25) until disease progression or unacceptable toxicity.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed doses:</b> If a daratumumab/hyaluronidase dose is missed, administer the dose as soon as possible and adjust the dosing schedule to maintain the dosing interval.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Premedication:</b> Administer a corticosteroid, an antipyretic, and an antihistamine 1 to 3 hours prior to each daratumumab/hyaluronidase dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Corticosteroid:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Monotherapy:<b> IV or Oral:</b> Methylprednisolone (or equivalent) 100 mg; consider reducing the dose to 60 mg following the second daratumumab/hyaluronidase dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Combination therapy: <b>IV or Oral:</b> Dexamethasone 20 mg (or equivalent) prior to each daratumumab/hyaluronidase dose. If dexamethasone is the background regimen-specific corticosteroid, the dexamethasone treatment dose will serve as the corticosteroid premedication on daratumumab/hyaluronidase administration days. Do not administer background regimen-specific corticosteroids (eg, prednisone) on daratumumab/hyaluronidase days when patients receive dexamethasone (or equivalent) as a premedication.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Antipyretic:</i>
<b>Oral:</b> Acetaminophen 650 to 1,000 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Antihistamine:</i>
<b>IV or Oral:</b> Diphenhydramine 25 to 50 mg or equivalent.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>In a clinical study, an optional leukotriene inhibitor (eg, montelukast 10 mg orally) was administered on day 1 of cycle 1 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32213342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32213342'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Postdose medication:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Monotherapy: </i>
<b>Oral:</b> Methylprednisolone 20 mg (or equivalent dose of an intermediate or long acting corticosteroid) for 2 days starting the day after the daratumumab/hyaluronidase dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy: </i>Consider administering oral methylprednisolone ≤20 mg (or equivalent) beginning the day after the daratumumab/hyaluronidase dose. If dexamethasone or prednisone is administered the day after the daratumumab/hyaluronidase dose as part of background combination chemotherapy regimen, additional postdose corticosteroid therapy may not be necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">If the patient does not experience a major systemic administration-related reaction after the first 3 daratumumab/hyaluronidase doses, consider discontinuing the administration of corticosteroids (excluding any background regimen-specific corticosteroid).</p>
<p style="text-indent:-2em;margin-left:6em;">In patients with a history of chronic obstructive pulmonary disease, also consider short- and long-acting bronchodilators and inhaled corticosteroids. If no major systemic administration-related reaction occurs following the first 4 daratumumab/hyaluronidase doses, consider discontinuing these additional inhaled post medications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F54456360"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl 15 to 89 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, CrCl between 15 to 89 mL/minute did not have any meaningful effect on daratumumab/hyaluronidase pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;15 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F54456361"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (total bilirubin 1 to 1.5 times ULN and AST &gt; ULN): There are no dosage adjustments provided in the manufacturer's labeling; however, mild impairment did not have any meaningful effect on daratumumab pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dot drugH1Div" id="F54456363"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Refer to specific protocol or to Dexamethasone, Prednisone, Lenalidomide, Thalidomide, Pomalidomide, Bortezomib, Carfilzomib, Cyclophosphamide, or Melphalan monographs for dosing adjustment for toxicity when used in combination with daratumumab-based therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematologic toxicity:</b> No dose reductions of daratumumab/hyaluronidase are recommended; If myelosuppression occurs, consider withholding daratumumab/hyaluronidase dose to allow recovery of blood cell counts.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonhematologic toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Immediately and permanently discontinue daratumumab/hyaluronidase for anaphylactic reaction or life-threatening (grade 4) administration-related reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">Local reactions: Consider managing symptomatically.</p>
<p style="text-indent:-2em;margin-left:4em;">Ocular reactions (eg, acute myopia, anterior chamber angle narrowing, ciliochoroidal effusions): Interrupt daratumumab/hyaluronidase therapy; ophthalmologic exam recommended prior to reinitiation of therapy.</p></div>
<div class="block doe drugH1Div" id="F54456359"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F54377088"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (15%; grade 3: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (42%; grades 3/4: 14%), decreased neutrophils (55%; grades 3/4: 19%), decreased platelet count (43%; grades 3/4: 16%), leukopenia (65%; grades 3/4: 19%), lymphocytopenia (59%; grades 3/4: 36%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (13%), infusion related reaction (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (&lt;10%), hypertension (&lt;10%), hypotension (&lt;10%), peripheral edema (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (&lt;10%), skin rash (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (&lt;10%), hyperglycemia (&lt;10%), hypocalcemia (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (&lt;10%), constipation (&lt;10%), decreased appetite (&lt;10%), nausea (8%; grade 3: &lt;1%), vomiting (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (≤7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection (&lt;10%), influenza (&lt;10%), reactivation of HBV (&lt;10%), sepsis (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (&gt;1%), injection site reaction (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (6%), dizziness (&lt;10%), insomnia (&lt;10%), paresthesia (&lt;10%), peripheral sensory neuropathy (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (&lt;10%), back pain (10%), muscle spasm (&lt;10%), musculoskeletal chest pain (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (&lt;10%), cough (9%), dyspnea (6%), pneumonia (8%), pulmonary edema (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Positive indirect Coombs test</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction (including severe hypersensitivity reactions)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Acute angle-closure glaucoma, choroidal effusion (ciliochoroidal), myopia (acute)</p></div>
<div class="block coi drugH1Div" id="F54367995"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">History of severe hypersensitivity to daratumumab, hyaluronidase, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F54456313"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Daratumumab-based therapy may increase background therapy-induced neutropenia and thrombocytopenia. Higher rates of grade 3 or 4 neutropenia have been observed in patients with lower body weights.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac toxicity: Serious or fatal cardiac adverse reactions have been reported when administered in combination with bortezomib, cyclophosphamide, and dexamethasone for the treatment of light chain amyloidosis. Patients with NYHA Class IIIA or Mayo Stage IIIA disease may be at an increased risk for cardiac effects; patients with NYHA Class IIIB or IV disease were not included in clinical trials.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatitis B virus reactivation: Daratumumab-based therapy may be associated with hepatitis B virus (HBV) reactivation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Systemic administration-related reactions (including severe or life-threatening reactions) may occur with daratumumab/hyaluronidase. In a large, pooled safety population of patients who received daratumumab/hyaluronidase as monotherapy or in combination, 9% of patients experienced a systemic administration-related reaction; grade 2 and 3 events were observed. Systemic reactions occurred more commonly with the first injection; a small number of patients experienced a systemic reaction with the second and subsequent injections. The median time to onset was ~3 hours (range: 4 minutes to 3.5 days), although most systemic administration-related reactions occurred on the day of daratumumab/hyaluronidase administration. Delayed (occurring the day after daratumumab/hyaluronidase administration) systemic administration-related reactions have occurred rarely. Severe reactions included hypoxia, dyspnea, hypertension, tachycardia, and ocular reactions (eg, choroidal effusion, acute myopia, acute angle closure glaucoma); other signs/symptoms of systemic reactions may include respiratory symptoms (eg, bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, wheezing), as well as anaphylactic reaction, pruritus, fever, chills, nausea, vomiting, chest pain, hypotension, and blurred vision.</p>
<p style="text-indent:-2em;margin-left:4em;">• Local reactions: Local injection-site reactions have occurred with daratumumab/hyaluronidase, including rare grade 2 events. The most frequent local reaction was injection-site erythema. Local reactions occurred a median of ~5 minutes (range: up to ~7 days) after starting daratumumab/hyaluronidase administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Interference with determination of myeloma response: Daratumumab (a human IgG kappa monoclonal antibody) may be detected on serum protein electrophoresis and immunofixation assays that monitor for endogenous M-protein. Interference with these assays by daratumumab-based therapy may affect the determination of complete response and disease progression in some patients with IgG kappa myeloma protein.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Patients ≥65 years of age experienced a higher incidence of upper respiratory tract infection, urinary tract infection, dizziness, cough, dyspnea, diarrhea, nausea, fatigue, peripheral edema, weakness, hypotension, and pneumonia (compared to patients &lt;65 years of age).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Do not interchange: Daratumumab/hyaluronidase (for subcutaneous administration) and daratumumab (for IV administration) have different dosing and are <b>NOT</b> interchangeable.</p>
<p style="text-indent:-2em;margin-left:4em;">• Interference with serological testing: Through binding to CD38 on red blood cells, daratumumab-based therapy may result in a positive indirect antiglobulin test (indirect Coombs test). Daratumumab-mediated Coombs test positivity may persist for up to 6 months after the last dose. In addition, daratumumab (bound to red blood cells) masks antibody detection to minor antigens in the patient's serum; ABO and Rh blood type determination are not affected. Notify blood transfusion centers and blood banks that a patient has received daratumumab/hyaluronidase. Type and screen patients prior to treatment initiation.</p></div>
<div class="block foc drugH1Div" id="F54369807"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Darzalex Faspro: Daratumumab 1,800 mg and hyaluronidase-fihj 30,000 units per 15 mL (15 mL)</p></div>
<div class="block geq drugH1Div" id="F54369805"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54407927"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Darzalex Faspro Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1800-30000MG-UT/15ML (per mL): $729.49</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F54987165"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Darzalex SC: 1800 mg/15 mL (15 mL)</p></div>
<div class="block adm drugH1Div" id="F54456366"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Check label to ensure appropriate product is administered; daratumumab/hyaluronidase (subcutaneous) and daratumumab (IV) are different products and are <b>NOT</b> interchangeable. The volume of the dose of daratumumab 1,800 mg/hyaluronidase 30,000 units is 15 mL.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Allow refrigerated product to reach room temperature prior to administration. Administer into the subcutaneous tissue of the abdomen ~3 inches (7.5 cm) to the right or left of the navel over ~3 to 5 minutes. Daratumumab/hyaluronidase should be administered by a health care provider. Rotate injection sites for successive injections. Do not administer into areas where the skin is red, bruised, tender, hard, or areas where there are scars. Pause or slow down subcutaneous delivery rate if the patient experiences pain. If pain is not alleviated by pausing or slowing down delivery rate, select a second injection site on the opposite side of the abdomen to deliver the remainder of the dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Daratumumab/hyaluronidase is compatible with polypropylene, polyethylene, or PVC subcutaneous infusion sets, and with stainless steel transfer and injection needles. Do not administer other subcutaneous medications at the same site as daratumumab/hyaluronidase.</p></div>
<div class="block use drugH1Div" id="F54368005"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Light chain amyloidosis (newly diagnosed):</b> Treatment of newly diagnosed light chain amyloidosis (in combination with bortezomib, cyclophosphamide, and dexamethasone) in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Daratumumab/hyaluronidase is not indicated nor recommended for the treatment of light chain amyloidosis in patients who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma (newly diagnosed): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of newly diagnosed multiple myeloma (in combination with bortezomib, thalidomide, and dexamethasone) in adults who are eligible for autologous stem cell transplant.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of newly diagnosed multiple myeloma (in combination with bortezomib, melphalan, and prednisone) in adults who are ineligible for autologous stem cell transplant.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of newly diagnosed multiple myeloma (in combination with lenalidomide and dexamethasone) in adults who are ineligible for autologous stem cell transplant.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma (relapsed/refractory):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of relapsed or refractory multiple myeloma (in combination with lenalidomide and dexamethasone) in adults who have received at least 1 prior therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of relapsed or refractory multiple myeloma (in combination with bortezomib and dexamethasone) in adults who have received at least 1 prior therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of relapsed or refractory multiple myeloma (in combination with carfilzomib and dexamethasone) in adults who have received 1 to 3 prior lines of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of relapsed or refractory multiple myeloma (in combination with pomalidomide and dexamethasone) in adults who have received at least 1 prior line of therapy, including lenalidomide and a proteosome inhibitor.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of relapsed or refractory multiple myeloma (as monotherapy) in adults who have received at least 3 prior lines of therapy, which included a proteasome inhibitor and an immunomodulatory agent, or who are double refractory to a proteasome inhibitor and an immunomodulatory agent.</p></div>
<div class="block mst drugH1Div" id="F54456193"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Daratumumab/hyaluronidase may be confused with daclizumab, daratumumab, darolutamide, denosumab, dinutuximab, dostarlimab, dupilimumab, durvalumab, elotuzumab, isatuximab, pertuzumab/trastuzumab/hyaluronidase, rituximab/hyaluronidase, trastuzumab/hyaluronidase.</p>
<p style="text-indent:-2em;margin-left:4em;">Darzalex Faspro may be confused with Darzalex.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F54402594"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F54402591"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: Hyaluronidase may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.  Management: Do not use hyaluronidase to enhance the dispersion or absorption of alpha-/beta-agonists. Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihistamines: May diminish the therapeutic effect of Hyaluronidase.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May diminish the therapeutic effect of Hyaluronidase.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Hyaluronidase may enhance the adverse/toxic effect of Local Anesthetics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenylephrine (Systemic): Hyaluronidase may enhance the vasoconstricting effect of Phenylephrine (Systemic).  Management: Do not use hyaluronidase to enhance the dispersion or absorption of phenylephrine. Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May diminish the therapeutic effect of Hyaluronidase.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54456232"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who may become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Daratumumab/hyaluronidase may be used as monotherapy or in combination with other anticancer agents. When used as monotherapy, patients who may become pregnant should use effective contraception during therapy and for 3 months after the last daratumumab/hyaluronidase dose. If daratumumab/hyaluronidase is used in combination regimens (eg, lenalidomide, thalidomide, pomalidomide), pregnancy testing and contraception requirements for those agents should also be followed.</p>
<p style="text-indent:0em;margin-top:2em;">Refer to the Daratumumab, Hyaluronidase, and other individual monographs (when using combination regimens) for additional information.</p></div>
<div class="block pri drugH1Div" id="F54456231"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action, in utero exposure to daratumumab/hyaluronidase may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Daratumumab/hyaluronidase may be used as monotherapy or in combination with other anticancer agents. Daratumumab/hyaluronidase is contraindicated for use in pregnancy when used in combination with some anticancer agents (eg, lenalidomide, thalidomide, pomalidomide).</p>
<p style="text-indent:0em;margin-top:2em;">Refer to the Daratumumab, Hyaluronidase, and other individual monographs (when using combination regimens) for additional information.</p></div>
<div class="block brc drugH1Div" id="F54456233"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if daratumumab/hyaluronidase is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during maternal treatment with daratumumab/hyaluronidase. Daratumumab/hyaluronidase may be used as monotherapy or in combination with other anticancer agents; refer to the Daratumumab, Hyaluronidase, and other individual monographs (when using combination regimens) for additional information.</p></div>
<div class="block mop drugH1Div" id="F54456364"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Blood type (type and screen prior to initiating therapy). CBC periodically. Evaluate pregnancy status prior to use in patients who may become pregnant. Monitor for signs/symptoms of hypersensitivity (systemic and local reactions). Monitor for cardiac toxicity; in patients with cardiac involvement of light chain amyloidosis, monitor more frequently for cardiac adverse reactions. Monitor for signs/symptoms of HBV reactivation, infection, ocular adverse reactions, and bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F54456346"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Daratumumab is an IgG1κ human monoclonal antibody directed against CD38. CD38 is a cell surface glycoprotein which is highly expressed on myeloma cells. By binding to CD38, daratumumab inhibits the growth of CD38-expressing tumor cells by inducing apoptosis directly through Fc mediated cross linking as well as by immune-mediated tumor cell lysis through complement dependent cytotoxicity, antibody dependent cell mediated cytotoxicity, and antibody dependent cellular phagocytosis. Hyaluronidase increases permeability of the subcutaneous tissue by depolymerizing hyaluronan. At the recommended dose, hyaluronidase acts locally and the effects are reversible; permeability of subcutaneous tissue is restored within 24 to 48 hours.</p></div>
<div class="block phk drugH1Div" id="F54456349"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: SUBQ: Multiple myeloma: Central compartment: 5.2 L; peripheral compartment: 3.8 L; Light chain amyloidosis: 10.8 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SUBQ: 69%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: SUBQ: 20 days (multiple myeloma); 28 days (light chain amyloidosis).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: SUBQ: ~3 days (multiple myeloma); ~4 days (light chain amyloidosis).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: 119 mL/day (multiple myeloma); 210 mL/day (light chain amyloidosis).</p></div>
<div class="block phksp drugH1Div" id="F54456356"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Body weight: After administration of daratumumab 1,800 mg/hyaluronidase 30,000 units (monotherapy) for multiple myeloma, the mean maximum C<sub>trough </sub>after the eighth dose was 12% lower in the higher body weight (BW) group (&gt;85 kg) while the mean maximum C<sub>trough</sub> was 81% higher in the lower BW group (≤50 kg), when compared to the corresponding BW groups receiving daratumumab IV. When administered for light chain amyloidosis, the mean maximum C<sub>trough </sub>after the eighth dose was 22% lower in the higher BW group (&gt;85 kg) and 37% higher in the lower BW group (≤50 kg) as compared to patients with body weight of 51 to 85 kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: After administration of daratumumab 1,800 mg/hyaluronidase 30,000 units in patients with light chain amyloidosis, the mean maximum daratumumab C<sub>trough</sub> after the eighth dose was 24% higher in Black patients compared to White patients; Asian patients had 16% higher mean maximum C<sub>trough</sub> after the eighth dose compared to White patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58216152"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Darzquro</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Darzalex faspro</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Darzalex SC</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33216361">
<a name="33216361"></a>Chari A, Rodriguez-Otero P, McCarthy H, et al. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label phase II study. <i>Br J Haematol</i>. 2021;192(5):869-878. doi:10.1111/bjh.16980<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daratumumab-and-hyaluronidase-subcutaneous-drug-information/abstract-text/33216361/pubmed" id="33216361" target="_blank">33216361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Darzalex.1">
<a name="Darzalex.1"></a>Darzalex Faspro (daratumumab/hyaluronidase) [prescribing information]. Horsham, PA: Janssen Biotech Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34087126">
<a name="34087126"></a>Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. <i>Lancet Oncol.</i> 2021;22(6):801-812. doi:10.1016/S1470-2045(21)00128-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daratumumab-and-hyaluronidase-subcutaneous-drug-information/abstract-text/34087126/pubmed" id="34087126" target="_blank">34087126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daratumumab-and-hyaluronidase-subcutaneous-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32213342">
<a name="32213342"></a>Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. <i>Lancet Haematol</i>. 2020;7(5):e370-e380. doi:10.1016/S2352-3026(20)30070-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daratumumab-and-hyaluronidase-subcutaneous-drug-information/abstract-text/32213342/pubmed" id="32213342" target="_blank">32213342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moreau.1">
<a name="Moreau.1"></a>Moreau P, Chari A, Haenel M, et al. Subcutaneous daratumumab (DARA SC) plus standard-of-care (SoC) regimens in multiple myeloma (MM) across lines of therapy in the phase 2 pleiades study: initial results of the Dara SC plus carfilzomib/dexamethasone (D-Kd) cohort, and updated results for the Dara SC plus bortezomib/melphalan/prednisone (D-VMP) and Dara SC plus lenalidomide/dexamethasone (D-Rd) cohorts. <i>Blood</i>. 2020;136(suppl 1):28-30. https://ashpublications.org/blood/article/136/Supplement%201/28/471077/Subcutaneous-Daratumumab-DARA-SC-Plus-Standard-of.</div>
</li></ol></div><div id="topicVersionRevision">Topic 128088 Version 104.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
